IGC Pharma, Inc.
IGC
$0.32
$0.000.72%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -41.77% | -0.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.77% | -0.61% | |||
| Cost of Revenue | -47.13% | -1.14% | |||
| Gross Profit | -35.71% | 0.00% | |||
| SG&A Expenses | 17.01% | 94.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.57% | 24.44% | |||
| Operating Income | -52.42% | -30.10% | |||
| Income Before Tax | -13.88% | -33.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.88% | -33.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.88% | -33.58% | |||
| EBIT | -52.42% | -30.10% | |||
| EBITDA | -57.86% | -34.63% | |||
| EPS Basic | -4.15% | -28.67% | |||
| Normalized Basic EPS | -5.00% | -20.00% | |||
| EPS Diluted | -4.15% | -28.67% | |||
| Normalized Diluted EPS | -5.00% | -20.00% | |||
| Average Basic Shares Outstanding | 8.95% | 4.32% | |||
| Average Diluted Shares Outstanding | 8.95% | 4.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||